Clinical trials
Colitis clinical trials
Below are recruiting colitis clinical trials, each written for real people, not researchers. We’re tracking 326 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05666960RecruitingPhase 1
Study drug R-3750 for mild to moderate ulcerative colitis
This Phase 1 study tests whether R-3750 is safe in people with mild to moderate ulcerative colitis and looks for early signs it could help. You may be able to join if you have stable treatment, confirmed diagnosis, and meet several health and medication timing rules.
Valencia, CaliforniaAges 18–65 - NCT05791487Recruiting
Diet plus oral budesonide for mild to moderate ulcerative colitis
This trial studies whether combining a specific diet with an oral steroid called budesonide can calm symptoms in people with mild to moderate ulcerative colitis. It may help reduce inflammation in the colon while building on stable current treatments.
AfulaAges 17–65 - NCT07012395RecruitingPhase 2
Long-acting antibodies for moderate to severe ulcerative colitis
This study tests new long-acting antibodies, given alone or in combination, for people with moderate to severe ulcerative colitis. The goal is to see if these treatments can help reduce inflammation and improve symptoms.
Canoga Park, CaliforniaAges 18–75 - NCT07415044RecruitingPhase 2
Study of LY4268989 for moderate to severe ulcerative colitis
This study tests an investigational medication called LY4268989 for adults with moderate to severe ulcerative colitis (UC). It's for people who have tried other treatments without success. The goal is to see if the drug can reduce inflammation and improve symptoms.
Phoenix, ArizonaAges 18–80 - NCT06420492RecruitingPhase 2
New treatments for severe ulcerative colitis flare
This trial tests new therapies for people with a severe UC flare that hasn't improved after 5 days of high-dose steroids. It aims to find more effective options to control symptoms and avoid hospitalization.
Chestnut Hill, MassachusettsAges 18–75 - NCT06899789Recruiting
Long-term follow-up of colitis from checkpoint inhibitors
This study follows people who developed colitis (inflammation in the colon) after receiving immune checkpoint inhibitors for cancer. Researchers want to learn about long-term effects and outcomes.
Pavia, PaviaAges 18 years+ - NCT07652294Enrolling by invitationPhase 2
Long-term safety of antibodies for IBD maintenance
This trial is testing long-lasting antibodies given alone or in combinations to keep IBD under control over the long term. It's for people who already did well in the initial study and want to continue treatment.
Lancaster, CaliforniaAges 18 years+ - NCT07463183RecruitingPhase 2
Study of MK-8690 for moderate to severe ulcerative colitis
This trial tests an investigational drug called MK-8690 for people with moderate to severe ulcerative colitis (UC) who haven't responded well to other treatments or can't tolerate them. The study aims to see if the drug can help control UC symptoms safely.
Anaheim, CaliforniaAges 18–75 - NCT04844606RecruitingPhase 3
Mirikizumab for kids with ulcerative colitis or Crohn’s
This study checks whether continuing mirikizumab (a medicine that calms gut inflammation) helps children with ulcerative colitis or Crohn’s disease after prior study treatment. It aims to see if staying on the medicine is beneficial and safe over time.
San Francisco, CaliforniaAges 2–19 - NCT05628701Recruiting
Testing two UC surgery reconstructions after colectomy
This trial compares two ways of reconnecting the bowel after subtotal colectomy and ileostomy in people with ulcerative colitis (UC). It may help determine which surgical option works best when the rectum is calm enough to manage with topical mesalazine alone.
GothenburgAges 18–60 - NCT05726396RecruitingPhase 2
Microbiome therapy for steroid-resistant immune colitis
This Phase 2 pilot study tests a “restorative microbiota therapy” (RMT) to treat colitis caused by immune checkpoint inhibitors when standard treatments like steroids are not working. It aims to see if this approach is safe and practical, and may improve diarrhea and gut inflammation.
Brainerd, MinnesotaAges 18 years+ - NCT06067698Recruiting
Alpha lipoic acid for mild to moderate ulcerative colitis
This trial tests whether adding alpha lipoic acid (an antioxidant) to your usual mesalamine treatment helps control mild to moderate ulcerative colitis. It is for people newly diagnosed and not on other UC treatments.
TantaAges 18 years+ - NCT06311123Recruiting
Study of Ozanimod's Effects on Immune Cells in Ulcerative Colitis
This study looks at how the medicine ozanimod works in people with active ulcerative colitis. Researchers will use a special blood test to understand how the drug affects your immune system.
San Diego, CaliforniaAges 18 years+ - NCT06469424Recruiting
Safety of Tofacitinib in Ulcerative Colitis
This study follows people with moderately to severely active ulcerative colitis who are taking the medication tofacitinib (Xeljanz). It aims to track any safety concerns in a real-world setting, using information already collected in a European registry (UR-CARE).
BonheidenAges 18 years+ - NCT06598943RecruitingPhase 2
Study of two new drugs for ulcerative colitis
This study tests two experimental drugs, Eltrekibart and Mirikizumab, for adults with moderate to severe ulcerative colitis who have not responded well to other treatments. The goal is to see if these drugs can help control the disease.
Chandler, ArizonaAges 18–75 - NCT06655415Recruiting
Study for family members at risk of inflammatory bowel disease
This study follows people who have a parent, sibling, or child with Crohn's disease or ulcerative colitis to help understand why some family members develop the condition. If you are 14 or older and do not already have IBD, you may be able to join.
Boston, MassachusettsAges 14 years+ - NCT06850727RecruitingPhase 2
Study of OD-07656 then vedolizumab for ulcerative colitis
This trial tests a new drug, OD-07656, followed by vedolizumab, in people with moderate to severe ulcerative colitis. It aims to see if this approach is safe and helps control symptoms when other treatments have not worked well.
BirtinyaAges 18–75 - NCT07333716RecruitingPhase 2
Desloratadine for mild to moderate UC
This trial tests whether desloratadine, an allergy medicine (antihistamine), can help reduce inflammation in people with mild to moderate ulcerative colitis. All participants must already be taking mesalamine and cannot be on other stronger UC treatments.
Shibīn al Kawm, MenofiaAges 18–65 - NCT07619638Recruiting
Microbiome Supplement for Mild-to-Moderate Ulcerative Colitis
This trial tests a specially designed supplement that aims to restore healthy gut bacteria in people with mild-to-moderate ulcerative colitis. The goal is to reduce inflammation and improve symptoms like rectal bleeding and bowel urgency.
IzmirAges 18–75 - NCT07632573RecruitingPhase 1
Safety Study of BDHK-2009 Tablets in Healthy Adults
This is an early-stage safety study testing a new experimental tablet called BDHK-2009 in healthy volunteers with no major illnesses. Researchers want to make sure the drug is safe and well-tolerated before testing it in people with medical conditions.
Hangzhou, ZhejiangAges 18–55 - NCT07791862Recruiting
Early risk study for relatives of IBD patients
This study looks at healthy family members of people with Crohn's disease or ulcerative colitis to find early signs of these conditions before symptoms appear. It may help doctors predict and prevent inflammatory bowel disease.
Seattle, WashingtonAges birth–55 years - NCT07428629Recruiting
Insomnia treatment trial for people with ulcerative colitis
This trial tests whether a sleep-focused therapy can help people with active ulcerative colitis who also have trouble sleeping. It aims to improve both sleep and UC symptoms.
Lebanon, New HampshireAges 18 years+ - NCT07606339Recruiting
Guselkumab for moderate-to-severe Crohn's or ulcerative colitis
This study tests guselkumab, a medication that reduces inflammation in the gut, for people with moderate-to-severe Crohn's disease or ulcerative colitis who haven't previously tried certain similar biologic drugs. The goal is to see how well it works and is tolerated in real-world use.
ViennaAges 18 years+ - NCT07196748RecruitingPhase 3
Icotrokinra for adults and teens with moderate to severe ulcerative colitis
This trial tests a new oral medication, icotrokinra, for people with moderately to severely active ulcerative colitis. It may be an option if you have not responded well enough to standard treatments or newer advanced therapies.
Chandler, ArizonaAges 12 years+
Hear when a new Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Colitis trials by city
Studies with a site in or near these metro areas.
Colitis trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for colitis?
- Yes. Clin2 currently lists 326 recruiting colitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a colitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a colitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.